We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: August 4, 2005
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
CollaGenex Pharmaceuticals
The objective of this study is to evaluate the safety and efficacy of 40 mg doxycycline controlled-release capsules administered once daily for the treatment of rosacea compared with a placebo.

Condition Intervention Phase
Rosacea Drug: doxycycline Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by CollaGenex Pharmaceuticals:

Primary Outcome Measures:
  • Change in total inflammatory lesion count

Secondary Outcome Measures:
  • Change from baseline in erythema scale scores
  • change from baseline in the investigator's global assessment (IGA) score
  • proportion of patients being clear or near-clear at endpoint

Estimated Enrollment: 528
Study Start Date: June 2004
Estimated Study Completion Date: April 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Healthy patients with rosacea
  • Males and females ≥18 years of age
  • 10 to 40 papules and pustules and ≤2 nodules
  • Score of 2 to 4 on the IGA
  • Presence of telangiectasia
  • Moderate to severe erythema

Main Exclusion Criteria:

  • Use of topical acne treatments or topical or systemic antibiotics
  • Use of systemic retinoids within 90 days of baseline
  • Use of an investigational drug within 90 days of baseline
  • Pregnant or nursing women
  • Women of childbearing potential not using an adequate form of contraception
  • Change in method of contraception within 4 months of baseline
  • Known hypersensitivity to tetracyclines
  • Surgeries that bypass or exclude the duodenum or achlorhydria
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00126399     History of Changes
Other Study ID Numbers: COL-101-ROSE-301+302
First Submitted: August 2, 2005
First Posted: August 4, 2005
Last Update Posted: December 9, 2005
Last Verified: August 2005

Keywords provided by CollaGenex Pharmaceuticals:
acne rosacea

Additional relevant MeSH terms:
Skin Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents